TP53 and myeloid neoplasm: Phase I trial (NCT04214860) was designed for dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with TP53-mutated myeloid malignancies.